Oncology blockbusters must target adjuvant settings to secure massive patient volumes.
Facing crowded markets and high clinical failure rates in metastatic cancers, drugmakers are shifting clinical development to post-surgical adjuvant settings with longer treatment windows and larger patient pools.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The first Phase 3 win for an individualized neoantigen therapy is sited in the adjuvant setting where treatment windows and patient volumes are largest.
The landmark Phase 3 victory for the personalized vaccine was secured in the post-surgical adjuvant setting where it could target patients with completely resected disease.
Merck is shifting Welireg's clinical focus from late-stage metastatic settings to the post-surgery adjuvant space to target kidney cancer patients earlier and capture larger patient volumes.
Moderna and Merck successfully validated their individualized neoantigen therapy by targeting patients in the high-volume adjuvant setting.
An investigational mRNA neoantigen therapy demonstrated clinical success specifically in the post-surgical adjuvant setting.
Following a trial failure in the metastatic setting, the developer redirected focus to the highly lucrative, high-volume early-stage adjuvant market.
Shifting the clinical focus of these blocking agents to early-stage adjuvant settings vastly expands candidate eligibility and treatment durations.
By moving Pluvicto earlier into the prostate cancer disease continuum, Novartis successfully expanded its eligible patient volume.
The checkpoint inhibitor halves recurrence risk in the curative-intent post-surgical setting where the largest treatable patient volumes live.
Oncology blockbusters are combining targeted therapeutics to establish superior clinical benefit in the post-surgical adjuvant setting, maximizing early patient market volumes.